Concert Pharmaceuticals Inc (CNCE) : Bvf Incil scooped up 523,304 additional shares in Concert Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,755,318 shares of Concert Pharmaceuticals Inc which is valued at $30,280,945.Concert Pharmaceuticals Inc makes up approximately 6.80% of Bvf Incil’s portfolio.
Other Hedge Funds, Including , Wall Street Associates sold out all of its stake in CNCE during the most recent quarter. The investment firm sold 23,300 shares of CNCE which is valued $256,067.Group One Trading boosted its stake in CNCE in the latest quarter, The investment management firm added 407 additional shares and now holds a total of 1,107 shares of Concert Pharmaceuticals Inc which is valued at $12,166.
Concert Pharmaceuticals Inc closed down -0.01 points or -0.10% at $9.71 with 1,49,181 shares getting traded on Thursday. Post opening the session at $9.68, the shares hit an intraday low of $9.4701 and an intraday high of $9.74 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Many Wall Street Analysts have commented on Concert Pharmaceuticals Inc. Stifel Initiated Concert Pharmaceuticals Inc on Jul 1, 2016 to “Buy”, Price Target of the shares are set at $23.
Concert Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company applying its DCE Platform to create novel small molecule drugs. The Company’s approach starts with approved drugs advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety tolerability and efficacy. It has a pipeline of wholly owned and collaboration programs. The Company has a number of clinical candidates under development such as CTP-656 which is a product candidate for the treatment of cystic fibrosis; AVP-786 which is being investigated for treatment of neurologic and psychiatric disorders including Alzheimers agitation; CTP-730 which is a product candidate for the treatment of inflammatory diseases and JZP-386 which is a product candidate for the treatment of narcolepsy.